PehLNarayanaswamySWangA. Comment: safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2019;53:101-102.
2.
RivosecchiRGroetzingerLMillerT. Comment: safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2019;53:103.
3.
WangXTirucheraiGMarburyTCet al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636. doi:10.1002/jcph.628
4.
MavrakanasTASamerCFNessimSJFrischGLipmanML.Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241-2248. doi:10.1681/ASN.2016090980
5.
ShahMTsadokAMJackeviciusCAet al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-1203. doi:10.1161/CIRCULATIONAHA.113.004777
6.
SiontisKCZhangXEckardAet al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the united states. Circulation. 2018;138:1519-1529.
